Related Articles
Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non‑small cell lung cancer Retraction in /10.3892/ol.2022.13595
ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer
High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage Ⅰ non-small cell lung cancer
Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo
ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126